ASAM CONTINUUM software will be the research and clinical assessment tool for one of the largest clinical trials in the history of addiction treatment. The U.S. Patient Centered Outcomes Research Institute (PCORI) has announced a $13 million award to the Treatment Research Institute (TRI) in Philadelphia for the 5-year study. Principal Investigator, David R. Gastfriend, MD, DFASAM, noted that the controlled study will randomly assign 800 opioid use disorder patients in Philadelphia, PA and Washington, D.C. to either standard care or a new, integrated care model, called PATH. PATH, or Personalized Addiction Treatment-to-Health, begins with the new national standard for comprehensive multidimensional assessment, the ASAM-endorsed CONTINUUM interview. Patients then receive Cognitive-Behavioral Therapy (CBT), Contingency Management (CM), Medication in Addiction Treatment (MAT), and Recovery Support Services with a Recovery Coach – all integrated within a primary care environment in Federally Qualified Health Centers (FQHCs). ASAM CONTINUUM and the new brief referral tool, CO-Triage, will be used for baseline and repeat follow-up assessments of Level of Care need and outcomes. This is the first time ASAM CONTINUUM software will be used in either Pennsylvania or the District of Columbia; it is already in use in California and Massachusetts.